Merck's Profits Rebound, Shares Jump 75% as Institutions Take Notice

What turned up

Several groups of selective institutions have recently been making similar trades in the stock of Merck & Co., a major pharmaceutical company. In two separate instances, groups of 13 and 7 of these professional investors, who are known for their detailed research, were observed moving in the same direction on the stock. This coordinated activity is what brought the company to our attention.

What the numbers say

Merck's financial results show a period of significant change, particularly in its profitability.

(in US$ billions)	2021	2022	2023	2024	2025
Revenue	$48.7	$59.3	$60.1	$64.2	$65.0
Net Income	$13.0	$14.5	$0.4	$17.1	$18.2
Operating Cash	n/a	$19.1	$13.0	$21.5	$16.5
Long-term Debt	$30.7	$28.8	$33.7	$34.5	$46.8
Cash	$8.1	$12.7	$6.8	$13.2	$14.6
Shareholders' Equity	$38.2	$46.0	$37.6	$46.3	$52.6

While revenue has grown steadily, the most striking figure is net income, which is the company's profit after all expenses. After a dramatic drop to $0.4 billion in 2023, profits recovered to $17.1 billion in 2024 and grew further to $18.2 billion in 2025. The company also took on more long-term debt, which rose to $46.8 billion in 2025. Over the last five years, the number of shares has slightly decreased, which means each remaining share represents a slightly larger piece of the company's earnings.

What the company has been doing

In late 2024, Merck reported changes to its directors or senior officers and amended its corporate bylaws. More significantly, in July 2025, the company announced it had committed to a restructuring or exit plan. This move came after the company had already reported its strong profit rebound for the 2024 fiscal year. Over the past two years, the company has consistently filed its required financial results and made a few other disclosures it judged important for investors to know.

What changed in the fine print

Between its 2024 and 2025 annual reports, Merck's management adjusted the risks it highlights to investors. The company added specific new warnings, including one stating that its blockbuster drug, Keytruda, "will decline materially" after its patent protection ends. This points to a significant, known future challenge.

At the same time, Merck dropped several previous warnings. It no longer highlights risks related to its business in China, general global pricing pressure, or the need for a successful new product pipeline. This shift suggests management's attention has moved from broader, industry-wide concerns to the specific, high-stakes challenge of managing the lifecycle of its most important product.

How the market has taken it

Investors have responded very positively to Merck over the past year, with the share price rising 75.5% in the 13 months ending in early October 2026. The market has paid close attention to the company's filings. An announcement in December 2025 saw trading volume at 3.6 times the normal level. Several earnings reports and other disclosures in 2026 also prompted trading volume nearly double the average, with the stock price making significant moves both up and down on those days. The overall trend, however, has been strongly upward.

What this doesn't tell you

• This analysis is based on public filings, which are backward-looking. It doesn't predict future performance or stock prices.
• We don't know the specific reasons why the groups of institutions made their trades, only that their activity was similar.
• The success of Merck's drug pipeline and its ability to manage the eventual decline of Keytruda is a major uncertainty not fully captured in past results.
• The long-term financial effects of the company's 2025 restructuring plan are not yet reflected in the reported numbers.
• The specific causes for the sharp drop in net income in 2023, while a pivotal event, are not detailed in this summary.